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The metabolic syndrome has reached pandemic level worldwide, and evidence is that estradiol plays a key
role in its development. The discovery of the second estrogen receptor, ERb, in tissues previously not consid-
ered targets of estradiol was a breakthrough in endocrinology. In the present review, we discuss how the
presence of ERb and the previously described ERa in tissues involved in glucose and lipid homeostasis
(brain, skeletal muscle, adipose tissue, pancreas, liver, and heart) may have important implications to risk
factors associated with the metabolic syndrome. Imbalance of ERa/ERb ratio in this ‘‘metabolic network’’
may lead to the metabolic syndrome.Introduction
The metabolic syndrome (MS) is characterized by obesity, dysli-
pidemia, hypertension, insulin resistance, and prothrombotic
and proinflammatory states, and affected patients are at in-
creased risk for heart diseases and diabetes mellitus (DM)
(Grundy, 2008). The pathogenesis ismultifactorial, but hormones
play a pivotal role in its development and progression. Numerous
clinical studies have now shown a correlation between estradiol
(E2) and several aspects of theMS (Salpeter et al., 2006). In addi-
tion, the development of transgenic mice in which the aromatase
enzyme, essential for E2 synthesis, was inactivated (ArKO mice)
confirmed the importance of E2 in glucose homeostasis and
obesity. Male and female ArKO mice have reduced glucose
oxidation and increased adiposity and insulin levels (Jones
et al., 2000). Male ArKO mice develop glucose intolerance and
insulin resistance that can be reversed by E2 treatment (Takeda
et al., 2003). Men lacking aromatase also present with hyperinsu-
linemia (Jones et al., 2006).
For decades, all the actions of E2 were ascribed to one
estrogen receptor (ER), ERa (Jensen, 1962). In 1996, however,
our group discovered ERb (Kuiper et al., 1996). The finding of
ERb in several tissues was a turning point in our understanding
of estrogen signaling. We now know that E2 is involved in
a plethora of mechanisms in physiology and disease in both
men and women. The use of transgenic mice in which ERa
(ERa/) and/or ERb (ERb/) have been knocked out brought
some insights into the specific roles of each receptor, and
a wealth of data suggest that ERa and ERb may have divergent
functions in carbohydrate and lipid metabolism.
In the present review, we discuss how the expression of ERa
and ERb in the brain, skeletal muscle, adipose tissue, liver,
pancreas, and cardiovascular system influences carbohydrate
and lipid homeostasis and related diseases.
E2 and the Central Regulation of Energy Homeostasis
The brain is made aware of the metabolic state of the body
through signals released from adipose tissue, skeletal muscle,
liver, pancreas, and gut. There is a wide variety of these signals,
including hormones (insulin, leptin, gut hormones), cytokines
(IL-6, TNF-a), and nutrients (glucose, free fatty acids, lipids).Anorexigenic and orexigenic signals from the CNS then induce
behavioral and metabolic changes targeting energy homeo-
stasis and survival.
In several mammals and in women, higher levels of E2 during
the estrus and menstrual cycles and pregnancy lead to
decreased food intake and fat accumulation. In contrast, ovari-
ectomy, antiestrogen treatment, and menopause lead to an
increase in food intake and meal size, effects that are reversed
by E2 replacement. These observations indicate that E2 has
anorexigenic functions in the CNS. Indeed, intracranial injection
of E2 in sheep and rats leads to anorexia. It is now clear that
these effects represent direct actions of E2 in the hypothalamus
(Roepke, 2009).
The main hypothalamic areas involved in food intake and
satiety are the arcuate nucleus (ARC), the lateral hypothalamus
(LH), the paraventricular nucleus (PVN), the ventromedial hypo-
thalamus (VMH), and the dorsomedial hypothalamus (DMH)
(Roepke, 2009). Several melanocortin receptors are expressed
throughout these nuclei, composing the melanocortin system,
and are one of the main regulators of hunger and satiety (Pillot
et al., 2011). Networks of neurons connect these hypothalamic
sites, and the end result on appetite and satiety will depend on
the interplay between neurons. ERa and/or ERb are expressed
in several of these nuclei, and it seems that the central actions
of E2 on metabolism involve changes of feeding behavior rather
than modulation of catabolism/anabolism of carbohydrates and
lipids.
In the ARC, several types of neurons and receptors of the
melanocortin system (MC3R andMC4R) are involved in the regu-
lation of appetite and respond to variations in glucose, lipids,
leptin, and insulin. The pro-opiomelanocortin (POMC) neurons
have an anorexigenic action and, when activated, reduce food
intake through the release of two peptides, a-melanocyte-
stimulating hormone (a-MSH) and cocaine-and-amphetamine-
regulated transcripts (CART). The neuropeptide Y (NPY) neu-
rons, on the other hand, release NPY hormone and agouti
gene-related protein (AgRP), which prevent the binding of
a-MSH to MC3R and MC4R, increasing food intake (Pillot
et al., 2011). Both ERs have been identified in the ARC. ERa is
predominantly expressed in the POMC neurons, while bothCell Metabolism 14, September 7, 2011 ª2011 Elsevier Inc. 289
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2011; Roepke, 2009). The melanocortin system is responsible
for the opposing actions of these neurons; however, so far a clear
relation between E2, MC3/4R, and food intake has not been
established (Polidori and Geary, 2002; Rocha et al., 2004).
The LH is the main target of ARC neurons and peptides and,
when stimulated, increases food intake. There are two types
of neurons involved in feeding in the LH, the melanin-concen-
trating hormone (MCH) neurons and the orexin neurons. Stimu-
lation of MCH neurons increases food intake and fat accumula-
tion while its inhibition leads to decreased food intake and
reduced fat accumulation. Orexin neurons are involved in sleep
and appetite, and their actions on feeding occur mainly through
neuronal projections to the PVN (Horvath, 2006; Nahon, 2006).
Both ERs have been identified in the LH, but since no ERs
have been detected in orexin or MCH neurons, it is currently
thought that E2 actions on these neurons are dependent on other
ER-expressing neurons of the LH and ARC (Muschamp and Hull,
2007).
The other three hypothalamic areas, DMH, PVN, and VMH, are
also mediators of ingestion and energy homeostasis and are
interconnected with the ARC and LH. The DMH secretes both
orexigenic (NPY) and anorexigenic (CART) peptides, and both
ERs have been identified in this nucleus. The PVN is highly
responsive to glucose, lipids, NPY, and AgRP, and its activation
leads to increased food intake (Horvath, 2006; Roepke, 2009).
The PVN is the region of the hypothalamus with the highest
expression of ERb and is reported to be weakly ERa positive
(Laflamme et al., 1998). Despite this apparent low level of ERa,
in rats and mice the ERa-selective agonist, PPT, rapidly results
in a decrease in food intake and increase in expression of
c-fos in the corticotrophin-releasing hormone (CRH)-expressing
cells in the PVN (Thammacharoen et al., 2009). The VMH is ERa
regulated and has an important function in the inhibition of food
intake through anorexigenic signals from the ARC (Xu et al.,
2003). Silencing of ERa in the VMH by RNA interference leads
to hyperphagia, obesity, decreased glucose tolerance, and
reduced energy expenditure (Musatov et al., 2007).
The role of ERb in the central regulation of feeding is less
known. In ovariectomized rats, there is increased food intake,
body weight, and abdominal fat accumulation, which can be
reversed by E2. However, administration of intracerebroventric-
ular E2 together with ERb antisense oligodeoxynucleotides abro-
gates the anorexic effects of E2. This suggests that the central
anorexic effects of E2 may occur via ERb (Liang et al., 2002).
In addition to its central actions, E2 also regulates peripheral
feedback hormones that influence feeding andmeal size through
their actions in the CNS.
Leptin is a potent anorexigenic and catabolic hormone
secreted by adipose cells that reduces food intake and increases
energy expenditure. Two well-studied mouse models of obesity
involve disturbances in leptin signaling. They are theOb/obmice,
in which leptin levels are low, and Agouti mice, in which leptin
levels are high. Leptin receptors have been identified in the
ARC, PVN, and VMH, where they colocalize with ERa (Diano
et al., 1998). E2 not only modulates leptin receptor mRNA in
the ARC and VMH, but also increases hypothalamic sensitivity
to leptin, altering peripheral fat distribution (Chakraborty et al.,
2008).290 Cell Metabolism 14, September 7, 2011 ª2011 Elsevier Inc.The importance of insulin and glucocorticoids in peripheral
carbohydrate and lipid metabolism is clear, but the role of the
two hormones in CNS-mediated metabolic actions is still a
matter of debate. As with leptin, gonadal hormones affect
peripheral fat distribution by modulating insulin sensitivity and
expression of both insulin and glucocorticoid receptors in the
hypothalamus (Genabai and Briski, 2010). Insulin receptors are
found in glucose-sensing neurons located in the ARC and VNH
(Genabai and Briski, 2010) and glucocorticoid receptors in the
PVN (de Kloet et al., 2005). In ERa/ mice the upregulation
of POMC, which is normally induced by leptin and insulin, does
not occur, and this leads to increased food intake (Hirosawa
et al., 2008).
Another important peptide mostly produced in the stomach
and regulated by E2 is ghrelin. It acts on growth hormone secre-
tagogue receptors (GHSR1a) located in the ARC and is a potent
stimulator of food intake (Kageyama et al., 2010). The function of
ERs on ghrelin-induced food intake has not yet been resolved.
It thus appears that of the two ERs, ERa plays a predominant
role in the CNS regulation of lipid and carbohydrate homeo-
stasis.
E2 Actions in Peripheral Tissues Modulate
Energy Homeostasis through ERs
Skeletal Muscle
Skeletal muscle is responsible for 75% of the insulin-induced
glucose uptake in the body. Upon binding to its receptors, insulin
activates a phosphorylation cascade that involves several
proteins, among them the insulin receptor substrate (IRS), phos-
phoinositide 3-kinases (PI3K), protein kinase B (Akt), and AMP-
activated protein kinase (AMPK), and leads to the translocation
of glucose transporter 4 (GLUT4) from cytoplasmic vesicles to
the cell membrane. Once docked on the plasma membrane,
GLUT4 permits the transport of glucose into the cell. GLUT4 is
highly expressed in muscle and represents a rate-limiting step in
the insulin-inducedglucoseuptake (Bjo¨rnholmandZierath, 2005).
During perimenopausal and postmenopausal periods, there is
a striking decline in muscle strength that can be reversed by
hormonal replacement therapy (HRT), suggesting that estrogens
and progesterone are important modulators of muscle physi-
ology (Phillips et al., 1993). Indeed, a meta analysis of data
from female patients receiving HRT confirmed the beneficial
effects of estrogens on muscle strength (Greising et al., 2009).
The mechanisms by which E2, through its actions on muscle,
regulates metabolism are unknown. However, data suggest
that in the physiological range, E2 is beneficial for insulin sensi-
tivity, whereas hypo- or hyperestrogenism is related to insulin
resistance (Livingstone and Collison, 2002).
E2 modulates glucose disposal mainly through its actions on
several proteins of the insulin signaling pathway and on the
expression and translocation of GLUT4. In rats exhibiting normal
glucose homeostasis, E2 stimulates the phosphorylation of Akt,
AMPK, and the Akt substrate TBC1D1/4 in soleus muscle
(Rogers et al., 2009). Administration of E2 to insulin-resistant
rats or mice increases IRS-1 content and the concentration of
the phosphorylated form of Akt in muscle, restoring insulin action
(Ordo´n˜ez et al., 2008; Riant et al., 2009). In aging female rats, E2
treatment improves glucose homeostasis mainly through its
ability to increase muscle GLUT4 content on the cell membrane
Figure 1. ERa and ERb in Skeletal Muscle
(A–G) Upon binding to insulin receptors on the cell membrane (A), insulin
signaling is triggered and several proteins are phosphorylated (B), leading to
the translocation of GLUT4-containing vesicles to the cell membrane (C),
where GLUT4 docks and permits the influx of glucose by facilitated diffusion
(D). ERs modulate insulin signaling and glucose uptake by affecting several
steps. Both ERs seem to activate the insulin signaling cascade (E). ERa
modulates GLUT4 translocation to the cell membrane and glucose uptake (F),
whereas ERb is a repressor of GLUT4 expression (G). IRS, insulin receptor
substrate; PI3K, phosphoinositide 3-kinase; AKT, protein kinase B; AMPK,
AMP-activated protein kinase; GLUT4, glucose transporter 4; P, phosphate.
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during the postnatal period leads to an immediate downregula-
tion of genes involved in glucose metabolism, lipid oxidation,
and energy uncoupling (GLUT4, carnitinepalmitoyl transferase
1b [Cpt1b], peroxisome proliferator-activated receptor delta
[PPARd], and uncoupling protein 3 [Ucp3]) in muscle (Alexander-
son et al., 2009). Treatment of ovariectomized female rats with
E2 yielding levels similar to those observed in pregnancy
decreased insulin sensitivity and reduced GLUT4 expression
and translocation in skeletal muscle (Barros et al., 2008).
Skeletal muscle expresses both ERs, and in mice ERb is the
predominant isoform (Barros et al., 2006; Galluzzo et al., 2009).
Although much more work is needed, some glimpses into the
role of each receptor have been gained from knockout mice
and from studies with selective estrogen receptor modulators
(SERMs). In ERb/ mice both glucose tolerance and insulin
release are normal or better than in wild-type (WT) mice (Bryzga-
lova et al., 2006; Foryst-Ludwig et al., 2008). ERa/ mice are
glucose intolerant and insulin resistant (Heine et al., 2000). The
causes of these ER-induced alterations in glycemia are multiple
and seem to involve several pathways not only in muscle, but
also in other tissues involved in regulation of glycemia. When
E2-deficient ArKO male mice are treated with a selective ERb
agonist, DPN, there is a decrease in GLUT4 expression inmuscle
(Barros et al., 2006). These data suggest a suppressive role of
ERb on GLUT4 expression. Indeed, in the absence of ERa there
is reduced glucose uptake in muscle (Bryzgalova et al., 2006).
These results indicated that unopposed ERb action might
have diabetogenic effects. Tamoxifen, an ER antagonist, had
no effect on glucose tolerance or insulin sensitivity in muscle in
WT or ERb/ mice, but in ERa/ mice, tamoxifen increased
GLUT4 expression and improved insulin sensitivity (Barros et al.,
2009). On the other hand, treatment with the ERa-selective
agonist, PPT, increases GLUT4 translocation to the cell mem-
brane of L6 myoblasts, and when ERa is silenced there is
a decreased translocation (Galluzzo et al., 2009). Treatment of
ovariectomized rats with PPT also increases glucose uptake
and GLUT4 expression in skeletal muscle (Gorres et al., 2011).
All together, these data suggest that ERs participate in almost
every step of insulin-induced and in some steps of insulin-inde-
pendent glucose uptake (Figure 1). It is evident that ERa and ERb
have distinct actions and that much more research is needed to
clearly identify the function of each receptor in muscle.
Adipose Tissue
Adipose tissue is a complex and highly active organ that partic-
ipates in a variety of processes, including carbohydrate and lipid
metabolism and endocrine, reproductive, and immune func-
tions. It interacts with the CNS as well as peripheral organs
and regulates its own function through autocrine and paracrine
factors. The size of the adipose tissue compartment reflects
the balance between whole-body energy intake and expenditure
(Frayn et al., 2003). Increased visceral adiposity has been linked
tomany components of theMS, like insulin resistance, dyslipide-
mia, hypertension, prothrombotic, and proinflammatory states.
Additionally, obesity is a risk factor for tumor development in
both men and women.
E2 prevents accumulation of visceral fat, increases central
sensitivity to leptin, increases the expression of insulin receptors
in adipocytes, and decreases the lipogenic activity of lipoproteinlipase in adipose tissue, preventing the development of obesity
and insulin resistance (Clegg et al., 2006). After menopause,
however, with decreased E2 production, there is increased
visceral fat mass and lipid accumulation and decreased lipid
utilization, increasing the risk for developing cardiovascular
diseases (CVDs) and insulin resistance (Wohlers and Spangen-
burg, 2010). The incidence of MS in postmenopausal women
parallels that of men.
Studies show that removal of gonadal hormones disrupts
several steps involved in glucose and lipid homeostasis in
adipose tissue, many of them reversed by E2 replacement. The
extent to which direct effects of estrogen on adipose tissue are
responsible for fat accumulation in estrogen deficiency states
is still under investigation.
In rats, ovariectomy increases body weight, intra-abdominal
fat, fasting glucose and insulin levels, and insulin resistance
followed by decreased phosphorylation of AMPK and its
substrate acetyl-CoA carboxylase in adipose tissue. Several
genes involved in the maintenance of glucose homeostasis are
also affected, i.e., decreased adiponectin, PPARg coactivator-
1a (PGC-1a), and uncoupling protein 2 (UCP2) and increased
resistin. Treatment with E2 restored normoglycemia and phos-
phorylation of AMPK; increased the expression of adiponectin,
PGC-1a, and UCP2; and decreased the expression of resistin
(Kim et al., 2010).
In mice, ovariectomy increased adipose triglyceride lipase
signaling, resulting in increased nonesterified fatty acids and
glycerol, which were attenuated by E2 treatment (Wohlers and
Spangenburg, 2010). Treatment of female mice with E2 leads
to decreased expression of lipogenic genes in adipose tissueCell Metabolism 14, September 7, 2011 ª2011 Elsevier Inc. 291
Figure 2. ERa and ERb in Adipose Tissue
(A–G) Similar to skeletal muscle (Figure 1), insulin-stimulated glucose uptake in
adipose tissue is modulated by ERs. ERa decreases proliferation and size of
adipocytes (A) and increases insulin signaling (B), GLUT4 translocation (C),
glucose uptake (D), and the expression of GLUT4 (E), whereas ERb increases
adipocyte size (A) and reduces PPARg expression (F) and activity (G). IRS,
insulin receptor substrate; PI3K, phosphoinositide 3-kinase; AKT, protein
kinase B; AMPK, AMP-activated protein kinase; PPARg, peroxisome pro-
liferator-activated receptor gamma; GLUT4, glucose transporter 4; P, phos-
phate.
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there is overt obesity, insulin resistance, and dyslipidemia (Jones
et al., 2000).
Men with aromatase deficiency have truncal obesity, elevated
blood lipids, and severe insulin resistance (Jones et al., 2006).
Oppositely, data from postmenopausal women undergoing E2
replacement therapy showed increase in triglyceride levels after
1 year of treatment, but no differences in the incidence of CVDs
(Anderson et al., 2004). Hyperestrogenism can disrupt GLUT4
expression and translocation in adipose tissue. In women, the
luteal phase of the menstrual cycle, late gestation, irregular
menstrual cycles, and gestational diabetes all can contribute to
insulin resistance (Garvey et al., 1993; Okuno et al., 1995).
Human subcutaneous and visceral adipose tissues express
both ERa and ERb, whereas only ERamRNA has been identified
in brown adipose tissue (Rodriguez-Cuenca et al., 2007). In male
mice, we have reported that perigonadal adipose tissue
expresses both ERs and that they are colocalized in the same
nuclei of some cells (Barros et al., 2009). The functions of the
two ERs in adipose tissue are not yet clear, but reports on
a man with ERa mutation or on patients with ERa or ERb poly-
morphisms together with data obtained from ER/ mice
provide hints on the function of each receptor. The only clinical
case of a nonfunctional ERa is a 28-year-old male patient who
presented with glucose intolerance, hyperinsulinemia, obesity,
and hyperestrogenism (Smith et al., 1994). Later, he developed
premature coronary artery disease associated with low levels
of total, LDL, and HDL cholesterol (Sudhir et al., 1997). Although
not all studies are in agreement, polymorphisms of ERa in
humans have been associated with risk factors for CVDs.
Indeed, ERa is now considered a candidate gene for obesity
(Casazza et al., 2010). In male mice, deletion of ERa causes
progressive increase in epididymal, perirenal, and inguinal
adipose tissue with advancing age. Epididymal and perirenal
adipocyte size is increased and adipocyte number is greater in
the fat pads. Female ERa/mice have increased fat, adipocyte
size, number, and leptin and cholesterol levels and smaller LDL
particles. Both males and females are insulin resistant with
impaired glucose tolerance (Heine et al., 2000).
E2 administered to ovariectomized mice fed a high-fat diet
preserved glucose tolerance and insulin sensitivity and improved
glucose tolerance inWTbut not in ERa/mice, suggesting that
targeting of the ERa could represent a strategy to reduce the
impact of high-fat-diet-induced type 2 DM (Riant et al., 2009).
We have also evaluated the role of ERs on GLUT4 function in
adipose tissue. The administration of tamoxifen to ERa/
and ERb/ mice resulted in different responses on GLUT4
expression. In ERa/ mice, tamoxifen did not interfere with
GLUT4 expression, whereas treatment of ERb/ mice with
tamoxifen substantially decreased it, suggesting that ERa is
the main regulator of GLUT4 expression in adipose tissue
(Barros et al., 2009). Ovariectomy of ERa/mice, i.e., removal
of E2/ERb signaling, reduced body fat and adipocyte size and
improved insulin and glucose metabolism, suggesting that ERa
and ERb have opposite functions on fat metabolism (Naaz
et al., 2002).
A study in patients with coronary artery disease revealed that
polymorphic changes in ERb are linked to increased body mass
index, elevated serum triglyceride, and high apolipoprotein B292 Cell Metabolism 14, September 7, 2011 ª2011 Elsevier Inc.concentrations. The authors propose ERb polymorphism as an
independent risk factor for the disease (Mansur Ade et al.,
2005). In mice, absence of ERb prevented accumulation of
triglycerides, preserved regular insulin signaling in liver and skel-
etal muscle, and improved whole-body insulin sensitivity and
glucose tolerance, suggesting a prodiabetogenic action of ERb
(Foryst-Ludwig et al., 2008). The use of ERb agonists in high-
fat-diet- and ovariectomy-induced obese WT mice, however,
reduced weight gain, serum cholesterol, leptin, glucose, and
fat accumulation (Yepuru et al., 2010).
Although there are not many studies on ERs in brown adipose
tissue andmetabolism, it has been shown that brown adipocytes
frommale rats have higher ERa expression compared to those of
female rats, suggesting that this receptor could have a role in
thermogenesis (Rodriguez-Cuenca et al., 2007).
In summary, growing evidence indicates that ERs modulate
several key steps in lipid and glucose metabolism (Figure 2).
An imbalance between ERa and ERb (ERa/ERb ratio) in adipose
tissue may have important implications for the development of
metabolic diseases.
Liver
Disturbances in liver function are related to dyslipidemia, insulin
resistance, and hyperglycemia. Hypercholesterolemia is more
common in males, whose lipid profile is characterized by lower
HDL, higher LDL and triglyceride levels, and larger VLDL parti-
cles. Additionally, studies indicate that the incidence of steatosis
is higher in men (Kolovou et al., 2009). In order to understand the
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postmenopausal women and the effects of E2-suppression
therapy in breast cancer patients. It was observed that E2 alone
increased HDL and triglycerides and decreased LDL, total
cholesterol, lipoprotein (a), and fasting insulin and glucose
levels and increased postchallenge glucose levels, suggesting a
temporal effect of E2 (Espeland et al., 1998). Recent studies have
demonstrated that the use of antiestrogen therapy, such as
tamoxifen and ovariectomy, leads to abnormal lipid profile and
steatosis, increasing the risk of CVDs and MS (Redig and Mun-
shi, 2010). In the E2-deficient ArKO mice, insulin resistance
develops due to hepatic steatosis (Takeda et al., 2003). It is
now recognized that dysfunction in fatty acid metabolism in
the liver is one of the main factors in the genesis of DM (McGarry,
2002).
ERa is the predominant ER isoform in hepatocytes (Gao et al.,
2008). ERbmRNA is present in human fetal liver (Brandenberger
et al., 1997) and hepatocytes of rats (Inoue et al., 2003).
One of the first indications of the importance of ERs in lipid
metabolism came from the previously mentioned patient with
a mutation in the ERa. In this man there were low levels of total,
LDL, andHDL cholesterol, apolipoprotein A-I, and lipoprotein (a).
Several studies in knockout mice have tried to elucidate the
participation of ERs in hepatic metabolism. ERa is the receptor
that controls inflammation, lipid, glucose, protein, and choles-
terol homeostasis in the liver:
(1) In the livers of ERa/ mice, there is increased glucose
production and expression of genes involved in hepatic
lipid synthesis and decreased expression of genes
involved in lipid transport (Bryzgalova et al., 2006). On
the other hand, the ERa agonist, PPT, increases the
expression of small heterodimer partner (Shp), signal
transducers and activators of transcription-3 (Stat3),
and phosphoenolpyruvate carboxykinases (Pck) 1 and 4
in the livers of WT mice. These are genes important for
glucose and lipid metabolism (Gao et al., 2008).
(2) ERamediates E2-induced protection against liver inflam-
mation (Evans et al., 2002). When ovariectomized mice
were treated with IL-1B to induce hepatic inflammation,
all three genotypes (WT, ERa/, and ERb/) re-
sponded to treatment with an increased expression of
cytokines, adhesion molecules, and transcriptional
factors. E2 antagonized the induction of these genes in
WT and ERb/ but not in ERa/ mice.
(3) ERa protects the liver from hypercholesterolemia. Treat-
ment of mice with acolbifene, an ER agonist, decreased
weight, fat mass, plasma cholesterol, and triglyceride
and cholesterol liver content in WT but not in ERa/
mice (Lemieux et al., 2005).
(4) ERa is essential for glucose tolerance and insulin sensi-
tivity. Genetically obese ob/ob mice respond to PPT
with improved glucose tolerance and insulin sensitivity.
PPT modulates genes involved in hepatic lipid meta-
bolism, increasing the expression of Stat3 and decreas-
ing that of glucose-6-phosphatase, CCAAT/enhancer-
binding protein b, Kru¨ppel-like factor 15, GLUT1, and
VLDL receptor. These results lead to the conclusion that
E2 via ERa is antidiabetogenic (Lundholm et al., 2008).The beneficial effects of E2 via ERa are also evident in
mice fed a high-fat diet (Ribas et al., 2010).
Although ERa is the dominant receptor in liver, ERb does have
some functions in this tissue. ERb/ mice fed a high-fat diet
had decreased liver weight due to reduced triglyceride accumu-
lation. They had increased hepatic insulin sensitivity accompa-
nied by increased insulin-stimulated Akt phosphorylation, sug-
gesting that ERb might be diabetogenic. The phenotype
observed in ERb/ mice, increased body weight and fat
mass with improved hepatic and muscular insulin sensitivity,
may be due to reduced accumulation of triglycerides and
increased insulin sensitivity in liver and muscle (Foryst-Ludwig
et al., 2008).
Pancreas
Studies evaluating the role of E2 in pancreatic islets and insulin
secretion date back to the 1940s, when it was demonstrated
that administration of E2 to rats increases insulin content in the
pancreas. Later, E2 was associated with islet hypertrophy and
regeneration after partial pancreatectomy in rats. E2 not only
influences islet size but is important in determining insulin
release from the b cells. Islets isolated from ovariectomized
mice respond to glucose with a smaller release of insulin than
do islets isolated from intact mice. Replacement of E2 in ovariec-
tomized mice normalizes the response. In women, insulin secre-
tion after menopause does not appear to be different from that
of premenopausal women. However, glucose tolerance tests
showed that in the postmenopausal period, there is both
reduced insulin secretion and reduced elimination. The overall
effect is maintenance of insulin levels, similar to that in premen-
opausal women (Godsland, 2005).
During HRT or use of hormone contraceptives, lower doses of
E2 increase insulin secretion, sensitivity, and elimination. Higher
doses of E2 seem to have a time-dependent effect on insulin
secretion. In the short term, hyperestrogenism is related to
reduced insulin secretion, whereas in the long term, increased
secretion is observed. E2 has rapid effects on b cells, regulating
membrane depolarization, Ca2+ influx, insulin secretion, and
overall glycemia (Alonso-Magdalena et al., 2006). In addition to
this, E2 is an important regulator of b cell inflammation and
apoptosis (Yamabe et al., 2010).
Both ERs have been identified in the nucleus and cell
membrane of b cells (Alonso-Magdalena et al., 2008; Nadal
et al., 2009). One of the first studies to confirm the participation
of ERs in regulation of pancreatic b cell function compared the
effects of low doses of bisphenol A (BPA), an endocrine disruptor
with estrogenic activity, and E2 on insulin secretion and content
in mice and isolated b cells. The results showed that both E2 and
BPA increased insulin secretion and reduced glucose plasma
levels through two distinct pathways. The first involved the
classical transcriptional activation, which was blocked by the
antagonist ICI; the second was a nonclassical pathway that
involved membrane ERs, was rapid, and was not influenced by
ICI (Alonso-Magdalena et al., 2006).
In ERb/mice, no changes have been observed in insulin or
glucose levels, but we have reported increased islet size and
delayed first-phase insulin release after glucose stimulation,
suggesting the importance of ERb in regulating islet size and
rapid insulin release in vivo (Barros et al., 2009). ERa/ miceCell Metabolism 14, September 7, 2011 ª2011 Elsevier Inc. 293
Figure 3. ERa and ERb in the Pancreas
(A–K) Influx of glucose into the b cell (A) increases ATP release from the
mitochondria (B) and closes the KATP channels (C), leading to membrane
depolarization (D). Ca2+ channels open and the intracellular Ca2+ content
increases (E), promoting the release of insulin from granules into the circulation
(F). ERa stimulates insulin synthesis (G) and ERb participates in insulin release
(H) and the closure of KATP channels (I). ERa and ERb also participate in the
E2-induced protective effects on apoptosis, via the membrane receptor
GPR30, preventing the decrease of insulin release (J). Additionally, ERa
regulates b cell proliferation and differentiation (K). GLUT2, glucose transporter
2; ATP, adenosine triphosphate; K+, potassium; Ca2+, calcium.
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of ERa results in islet dysfunction and hyperinsulinemia (Bryzga-
lova et al., 2006). In b cell islets isolated from Swiss albino mice,
PPT (ERa agonist) treatment resulted in increased insulin content
similar to that observed with E2, and ICI treatment blunted
ERa-induced insulin synthesis. Treatment of the islets with
DPN (ERb agonist) did not change insulin content. Further
support for the importance of ERa comes from studies of islets
isolated from WT, ERa/, and ERb/ mice. When cells
were submitted to E2 treatment, a strong response was
observed in cells from WT and ERb/ mice but not those
from ERa/ mice. In vivo, E2-induced insulin synthesis was
also abolished in ERa/ mice and in mice where ERa was
selectively knocked out in the pancreas. Surprisingly, by knock-
ing in a mutated ERa, it was discovered that E2-induced in-
sulin synthesis is independent of estrogen response element
(ERE). The pathway that regulates insulin synthesis involves acti-
vation of tyrosine kinase Src by extranuclear ERa (Wong et al.,
2010).
Much effort has been focused on regulation by E2 of the ATP-
sensitive potassium (KATP) channels in b cells. Closure of KATP
channels is a pivotal event in the glucose-induced insulin
release. Once the channel is closed, membrane depolarizes
and insulin is released. E2 and DPN reduced the activity of
KATP channels in b cells from WT mice and ERa/ mice cells,
but not those from ERb/ mice. Thus, it appears that ERb
mediates the estrogen-induced rapid inhibition of the KATP chan-
nels and, consequently, insulin release. The atrial natriuretic
peptide receptor (ANPR) is involved in KATP channel closure
and insulin release. Neither E2 nor DPN increases KATP channel
closure in ANPR knockout mice. In summary, E2-induced rapid
insulinotropic effects depend on ERb and involve KATP channels
and the ANPRs (Nadal et al., 2009).
One of the key features in both types 1 and 2 DM is b cell
apoptosis. E2 exerts antiapoptotic effects on these cells, but
the receptor that mediates this response was not identified until
recently. In the E2-deficient (ArKO) mice, there is increased
apoptosis of b cells, and these mice are prone to the develop-
ment of insulin-dependent DM when exposed to streptozotocin.
Treatment of these mice with E2 prevented apoptosis, main-
tained insulin production, and avoided the development of dia-
betes. In ERa/ mice, however, the protective effects of E2
were reduced, and in these mice there is b cell apoptosis and
insulin-dependent DM. Thus, ERa appears to be the ER that
protects b cells against apoptosis (Le May et al., 2006). These
protective effects of ERa on islet survival are independent of
the classical ERE and involve the G protein-coupled estrogen
membrane receptor (GPR30) (Liu et al., 2009).
ERa is also an important regulator of proliferation and differen-
tiation of human-islet derived cells (hIPCs). These cells express
only ERa and respond to E2 with increased proliferation and
reduced differentiation. Intriguingly, fetal hIPCs, which also
express ERa, do not respond to E2. This observation raises
the question of what other cell components are rate limiting to
certain actions of E2 during various phases of development
(Ren et al., 2010).
In conclusion, ERa and ERb are key players in the physiology
and pathology of the pancreas and seem to be of fundamental
importance in the proliferation, differentiation, and survival of294 Cell Metabolism 14, September 7, 2011 ª2011 Elsevier Inc.b cells and in the regulation of insulin synthesis and release.
E2/ER regulation of pancreatic function involves both genomic
and rapid nongenomic phenomena (Figure 3). Elucidation of
these intertwined estrogen signaling pathways is essential for
our understanding of b cell adaptation during high metabolic
demand and insulin resistant states and will most likely lead us
to novel therapies for b cell-related diseases and prevention of
apoptosis of b cells during stress periods.
Cardiovascular System
CVDs are the leading cause of death in men and women.
Although premenopausal women are protected against CVDs,
postmenopausal women have the same risk for this disease as
domen. In apparent contradiction, E2 appears to be responsible
for the increased prevalence of risk factors, such as hyperten-
sion and hyperlipidemia, and mortality rates in women. Several
studies indicate that exposure to physiological levels of E2
during the reproductive age is cardioprotective, whereas
hyper/hypoestrogenism, irregular E2 cyclicity, and reduced
length of reproductive life are correlated with increased CVDs.
For many years the protective effects of E2 were thought to
come from its ability to reduce LDL, increase HDL, slightly
decrease atherosclerosis, and increase reperfusion after
ischemia. However, recent trials have failed to confirm this asso-
ciation in postmenopausal women receiving HRT (Saltiki and
Alevizaki, 2007; Villablanca et al., 2010).
ERs have been identified in the vascular endothelium, vascular
smooth muscle (VSMC) and adventitial cells, and macrophages
of blood vessels. At present, there is no consensus of opinion as
to whether or not there is expression of ER in cardiac muscle.
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adult myocytes, fibroblasts, cardiomyocyte mitochondria, and
ventricle and atrial cells. In addition to ERs, the E2-responsive
membrane receptor GPR30 has been identified in cardiomyo-
cytes (Villablanca et al., 2010).
Delineation of the specific functions of ERa and ERb in the
cardiovascular system is a daunting task. The ER knockout
mice have revealed that ERa has protective effects on vascular
injury, whereas ERb ameliorates reperfusion after ischemic injury
and protects against ventricular hypertrophy and cardiomyocyte
apoptosis.
Ovariectomized WT and ERa/ mice without E2 replace-
ment had defective response to carotid injury, i.e., increased
medial areas andmatrix deposition. Treatment with E2 improved
response in the WT group but not in ERa/ mice, suggesting
that ERa mediates the protective effects of E2 (Pare
et al., 2002). Loss of ERa leads to dysfunction of the coronary
endothelium. In a model of ischemia followed by reperfusion
(I/R), WT and ERa/ ovariectomized mice develop coronary
endothelial dysfunction that can be reversed with E2 in WT but
not in ERa/ mice or in mice in which ERa was inactivated in
the endothelium (Favre et al., 2010).
Reduction of vascular endothelial growth factor (VEGF) is
thought to be one of the underlying causes of coronary heart
disease in postmenopausal women, and experiments with
knockout mice have supported this contention: studies in
ERa/ mice have revealed that ERa regulates several steps
in the VEGF signaling pathway. In ERa/ mice, but not in
ERb/ mice, there is reduced coronary capillary density
accompanied by reduced expression of VEGF and its signaling
proteins (AKT and endothelial nitric oxide synthase [eNOS]).
Thus, the protective effects of E2 on cardiac vasculature involve
the activation of VEGF signaling via ERa (Jesmin et al., 2010).
ERb/ mice develop systolic and diastolic hypertension
as they age, characterized by heart dilatation, nuclear shape
distortion, and displacement of lamins. These are predictable
changes observed in primary hypertension. We could not detect
ERb in the heart and suggest that E2 action in the myocardium
could be indirect (Fo¨rster et al., 2004). On the other hand, other
groups have suggested that ERb has important roles in cardiac
muscle and postischemic reperfusion of the heart. Gabel et al.
have reported that upon infarction injury, WT male mouse hearts
recover less and are more necrotic than female hearts. This
female advantage was lost in ERb/ but not in ERa/ mice
(Gabel et al., 2005). In addition, ERb/ mice are reported to
have increased mortality and aggravation of heart failure after
myocardial infarction (Pelzer et al., 2005). These data suggest
that ERb may have a protective role in ischemic lesions of the
heart.
Activation of the enzyme angiotensin II has a major influence
on development of myocyte hypertrophy and involves the
activation of extracellular signal-regulated kinase (ERK) MAPK
and induction of calcineurin and myosin heavy chain (MHC)
b expression. It is known that the E2-induced protection of
cardiac muscle is due to the inhibition of angiotensin II and its
signaling pathway. ER knockout mice have revealed that ERb
is the receptor involved in this mechanism: Treatment with
E2 reduced left ventricle hypertrophy and fibrosis, maintained
normal expression of MHC, and inhibited the activation of ERKMAPK and calcineurin in WT and ERa/ but not in ERb/
mice (Pedram et al., 2008).
ERb is also the receptor that protects the heart against
ischemic injury and facilitates remodeling after transverse aortic
constriction. E2-induced protection against apoptosis involves
the activation of the PI3K pathway and regulation of apoptotic
proteins. E2 improved reperfusion after ischemia, accompanied
by increased PI3K activity and expression of the antiapoptotic
protein BCL-2 and decreased expression of the proapoptotic
proteins caspase-3 and -8 in female WT mice, but not in female
ERb/ mice. These findings confirm that the antiapoptotic
actions of ERb in cardiomyocytes involve increased PI3K
signaling and point to a different regulation between males and
females (Fliegner et al., 2010; Wang et al., 2009).
Deletion of ERb exacerbated constriction-induced increase in
cardiomyocyte size in both sexes and increased the expression
of matrix-related genesmainly in males. Furthermore, in ERb/
mice, increased expression of proapoptotic genes in males and
the number of apoptotic nuclei in both sexes were observed.
Fibrosis was increased in both male and female ERb/ mice.
All together, these results suggest that E2 acting via ERb has
protective effects on fibrosis and apoptosis and may reduce
progression to heart failure (Fliegner et al., 2010).
The beneficial effect of ERb in the heart includes protection of
females from ventricular hypertrophy and fibrosis. ERb/mice
are more prone to develop left ventricular hypertrophy and
collagen deposition in response to deoxycorticosterone, an
agent known to induce left ventricle hypertrophy. There was
also reduced expression of the antihypertrophic p38 MAPK
and increased expression of calcineurin. Thus, ERb protects
against maladaptive dilatative cardiac fibrosis in females
(Gu¨rgen et al., 2011).
Abnormal proliferation of VSMCs, vasoconstriction, and
atherosclerosis are important components of CVDs, and the
role of E2 in these processes involves both ERs through
distinct pathways. A recent study has demonstrated that E2
reduces aorta neointima formation after injury through the mito-
chondrial antioxidant enzymemanganese superoxide dismutase
(MnSOD), which requires the transcription factor Kruppel-like
factor-4 (KLF4). In cultured rat aortic VSMCs, binding of E2 to
ERa increased the expression of KLF4 and reduced cell prolifer-
ation by 50% (Sivritas et al., 2011). ERa has also been shown to
reduce high-glucose-induced human VSMC proliferation via
ERa, by downregulating reactive oxygen species (ROS)-medi-
ated ERK activation (Ortmann et al., 2011). The use of a phytoes-
trogen, farrerol, on the other hand, decreased fetal bovine
serum-induced VSMC proliferation in rats via ERb, by inhibition
of DNA synthesis, arrest of G1 phase, and suppression of
ERK1/2 phosphorylation (Li et al., 2011). ERa stimulation acti-
vates a protein kinase G signaling pathway that opens large-
conductance calcium- and voltage-activated potassium channel
(BKCa) and intermediate-conductance calcium-activated potas-
sium (IKCa) channels, triggering relaxation (Alda et al., 2009). In
apo-E (a model of atherosclerosis) mice crossed with ERa/
mice, it was observed that the protective effects of E2 were abol-
ished, highlighting protective effects of ERa (Hodgin et al., 2001).
ERb induces relaxation by activating an adenylate cyclase/cyclic
AMP/protein kinase A pathway that opens chloride and potas-
sium channels (Valero et al., 2011) and exerts protective effectsCell Metabolism 14, September 7, 2011 ª2011 Elsevier Inc. 295
Cell Metabolism
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of heat shock proteins in vascular macrophages (Rayner et al.,
2009). The use of an ERb agonist in ovariectomized apo-E
knockout mice improved aortic atherosclerosis by reducing
34% of total and 75% of dense lesions (Sun et al., 2011).
However, additional studies also indicate the participation of
both ERs in the development of atherosclerosis (Rayner et al.,
2010). Further research is needed to clarify the role of each ER
in this disease.
In addition to the roles of ERs in the cardiovascular system, the
cholesterol metabolite 27-hydroxycholesterol (27OHC) binds to
and modifies the function of ERa and ERb. Much of the subop-
timal activity of HRTs is believed to be caused by competition
of 27OHC for ERE binding sites, reducing mainly the positive
ERa-induced effects on this system (Umetani and Shaul, 2011).
All in all, the mechanisms through which E2 directly regulates
the cardiovascular system are complex and involve multiple
actions in cardiac and vascular cells. Most of these actions are
mediated by ERa and ERb and involve genomic and nongenomic
pathways. Additionally, the participation of the membrane
GPR30 provides an alternative to the classical E2/ER pathway.
Research focused on the development of drugs capable of
modulating the specific signaling pathways of ERs and GPR30
would not only help to clarify the role of each receptor but might
also lead to new therapies for CVD.
Final Considerations
In this reviewwe aimed to dissect and illustrate the specific func-
tions of ERa and ERb in the ‘‘metabolic network’’ composed of
tissues involved in whole-body glucose and lipid metabolism.
However, wemust not forget the fundamental concept proposed
by the great French physiologist, Claude Bernard, the Milieu
Inte´rieur. It is clear now that both ERa and ERb participate in
numerous mechanisms in this intricate regulation with tissue
specificity, but these mechanisms will never be completely
understood if they are not considered in the context of a whole
system. Each organ discussed in this review has fundamental
roles in metabolism, and these tissues are dependent on each
other for homeostatic regulation of the body. It is therefore
reasonable to speculate that homeostasis depends on the equi-
librium between ERa and ERb in the metabolic network. We
hypothesize that an imbalance in the ERa/ERb ratio could trigger
a chain of events and lead to systemic diseases, such as MS.
One important question emerges, though: what comes first,
the imbalance of ERa/ERb or the disease?
Unfortunately, with our present knowledge on the subject, we
cannot propose new therapies for the prevention and treatment
of glucose- and lipid-related diseases, but continuous dissec-
tion of these mechanisms with an emphasis on integrative
physiology could lead to new therapeutic options in the future.
Additionally, the development of tissue-specific SERMS by the
pharmaceutical industry is a fundamental tool needed for future
research.
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